Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Not all antidepressants are created equal — at least for the long haul. A large systematic review published in The Lancet Psychiatry found that escitalopram, duloxetine, and agomelatine deliver better sustained responses in major depressive disorder (MDD) compared to other antidepressants, including the widely used fluoxetine. The findings, drawn from 115 studies and over 30,000 participants, could help clinicians and patients make more informed treatment choices.
Not all antidepressants are created equal — at least for the long haul. A large systematic review published in The Lancet Psychiatry found that escitalopram, duloxetine, and agomelatine deliver better sustained responses in major depressive disorder (MDD) compared to other antidepressants, including the widely used fluoxetine. The analysis, led by researchers at Radboud University Medical Centre in the Netherlands, pooled data from 115 studies involving more than 30,000 participants.
On the flip side, bupropion and reboxetine lagged behind, showing lower sustained response rates against multiple comparators. Reboxetine and milnacipran also stood out for higher rates of all-cause discontinuation — a key marker of tolerability. Escitalopram and duloxetine, meanwhile, showed better tolerability profiles with lower discontinuation rates compared to fluoxetine.
By the Numbers
Why it matters: With MDD affecting hundreds of millions globally, choosing the right antidepressant for long-term management is critical. These findings give prescribers a clearer, evidence-based framework to personalize treatment — balancing efficacy and tolerability for each patient.